KOL Insight

Eslicarbazepine has been approved in ex-US markets including the EU for years.

We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.

March 25, 2014

Schizophrenia and Bipolar Disorder Payer Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.

Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Schizophrenia and Bipolar Disorder KOL Interview – Germany

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

Rheumatoid Arthritis Payer Interview – UK

A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Rheumatoid Arthritis Payer Interview – Pennsylvania, US

A US payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Rheumatoid Arthritis KOL Interview – UK

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – New Jersey, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Rheumatoid Arthritis KOL Interview – California, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

Retinal Disorders (AMD and DME) Pulse

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).

October 27, 2014

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #2

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021

Respiratory Syncytial Virus (RSV) Prevention KOL Interview – US #1

This interview with a US-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

December 22, 2021